@article{baja_kelsey_ruslander_gieger_nolan_2022, title={A retrospective study of 101 dogs with oral melanoma treated with a weekly or biweekly 6 Gy x 6 radiotherapy protocol}, volume={4}, ISSN={["1476-5829"]}, url={https://doi.org/10.1111/vco.12815}, DOI={10.1111/vco.12815}, abstractNote={AbstractOne radiotherapy (RT) protocol used for canine oral melanoma (OM) gives 36 Gy total, in six weekly or biweekly fractions (6 Gy × 6). This retrospective study characterizes oncologic outcomes for a relatively large group of dogs treated with this protocol and determines whether radiation dose intensity (weekly vs. biweekly) affected either progression‐free or overall survival (PFS and OS). Dogs were included if 6 Gy × 6 was used to treat grossly evident OM, or if RT was used postoperatively in the subclinical disease setting. Kaplan–Meier statistics and Cox regression modelling were used to determine the predictive or prognostic value of mitotic count, bony lysis, World Health Organization (WHO) stage (I, II, III, or IV), using systemic anti‐cancer therapies, tumour burden at the time of RT (macroscopic vs. subclinical), radiation dose intensity (weekly vs. biweekly), and treatment planning type (manual vs. computerized). The median PFS and OS times for all dogs (n = 101) were 171 and 232 days, respectively. On univariate analysis PFS and OS were significantly longer (p = <.05) with subclinical tumour burden, WHO stages I or II, and weekly irradiation. On multivariable analysis, only tumour stage remained significant; therefore, cases were grouped by WHO stage (I/II vs. III/IV). With low WHO stage (I/II), PFS and OS were longer when irradiating subclinical disease (PFS: risk ratio = 0.449, p = .032; OS: risk ratio = 0.422, p = .022); this was not true for high WHO stage (III/IV). When accounting for other factors, radiation dose intensity had no measurable impact on survival in either staging group.}, journal={VETERINARY AND COMPARATIVE ONCOLOGY}, author={Baja, Alexie J. and Kelsey, Krista L. and Ruslander, David M. and Gieger, Tracy L. and Nolan, Michael W.}, year={2022}, month={Apr} } @article{yoshikawa_gieger_saba_fredrickson_kubicek_haney_ruslander_kelsey_mcentee_nolan_2021, title={Retrospective evaluation of intranasal carcinomas in cats treated with external-beam radiotherapy: 42 cases}, volume={35}, ISSN={["1939-1676"]}, url={https://doi.org/10.1111/jvim.16098}, DOI={10.1111/jvim.16098}, abstractNote={AbstractBackgroundLittle is known regarding the comparative efficacy of various irradiation strategies used to treat intranasal carcinomas (INC) in cats.ObjectivesInvestigate outcomes and prognostic factors associated with survival for cats with INC.AnimalsForty‐two cats with INC that underwent radiotherapy (RT).MethodsSingle‐arm retrospective study. Medical record review for cats with INC that underwent RT at 1 of 7 veterinary RT facilities. Irradiation protocols categorized as: definitive‐intent fractionated RT (FRT), definitive‐intent stereotactic RT (SRT), and palliative‐intent RT (PRT). Median overall survival time (OST) and disease progression‐free survival (PFS; documented by advanced transverse imaging, or recurrence of symptoms) were calculated. Associations between tumor stage, RT protocol/intent, and adjunctive treatment usage and outcome were calculated.ResultsCats underwent SRT (N = 18), FRT (N = 8), and PRT (N = 16). In multivariate modeling, cats received definitive‐intent treatment (DRT; FRT/SRT) had significantly longer median PFS (504 days, [95% confidence interval (CI): 428–580 days] vs PRT 198 days [95% CI: 62–334 days]; p = 0.006) and median OST [721 days (95% CI: 527–915 days) vs 284 days (95% CI: 0–570 days); p = 0.001]). Cats that underwent second DRT course at time of recurrence lived significantly longer than cats that received 1 RT course (either DRT or PRT [median OST 824 days (95% CI: 237–1410 days) vs 434 days (95% CI: 277–591 days); p = .028]).ConclusionIn cats with INC, DRT is associated with prolonged OST and PFS as compared to PRT. If tumor progression occurs, a second course of DRT should be considered.}, number={2}, journal={JOURNAL OF VETERINARY INTERNAL MEDICINE}, author={Yoshikawa, Hiroto and Gieger, Tracy L. and Saba, Corey F. and Fredrickson, Kirsha and Kubicek, Lyndsay and Haney, Siobhan and Ruslander, David and Kelsey, Krista L. and McEntee, Margaret C. and Nolan, Michael W.}, year={2021}, month={Mar}, pages={1018–1030} } @article{looper_malarkey_ruslander_proulx_thrall_2006, title={Epidermal growth factor receptor expression in feline oral squamous cell carcinomas}, volume={4}, ISSN={["1476-5829"]}, DOI={10.1111/j.1476-5810.2006.00091.x}, abstractNote={AbstractFeline oral squamous cell carcinomas (SCC) have a poor prognosis despite aggressive treatment with surgery, radiation and anticancer drugs. Overexpression of the epidermal growth factor receptor (EGFR), a membrane‐bound tyrosine kinase receptor, has been found in many human epithelial neoplasms, including oral SCC. EGFR overexpression has been associated with advanced disease and a poor prognosis. The purpose of this study was to determine whether feline oral SCC express EGFR. Thirteen formalin‐fixed paraffin wax‐embedded biopsy samples from feline oral SCC were analysed for EGFR expression using immunohistochemistry. Nine of 13 tumours (69%) were positive for EGFR expression, suggesting that altered EGFR expression plays a role in feline oral SCC and provides a rationale for a potential clinical benefit using EGFR inhibitors in combination with conventional treatments.}, number={1}, journal={VETERINARY AND COMPARATIVE ONCOLOGY}, author={Looper, J. S. and Malarkey, D. E. and Ruslander, D. and Proulx, D. and Thrall, D. E.}, year={2006}, month={Mar}, pages={33–40} } @article{hawkins_grooters_cowgill_proulx_davainis_ruslander_grindem_2006, title={Treatment of Conidiobolus sp pneumonia with itraconazole in a dog receiving immunosuppressive therapy}, volume={20}, DOI={10.1111/j.1939-1676.2006.tb00769.x}, abstractNote={Journal of Veterinary Internal MedicineVolume 20, Issue 6 p. 1479-1482 Open Access Treatment of Conidiobolus sp. Pneumonia with Itraconazole in a Dog Receiving Immunosuppressive Therapy Eleanor C. Hawkins DVM, DACVIM (SAIM), Eleanor C. Hawkins DVM, DACVIM (SAIM) Department of Veterinary Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, 27606; e-mail: eleanor_hawkins@ncsu.edu.Search for more papers by this authorAmy M. Grooters, Amy M. Grooters Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA.Search for more papers by this authorElizabeth S. Cowgill, Elizabeth S. Cowgill Department of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, NCSearch for more papers by this authorDavid R. Proulx, David R. Proulx Department of Veterinary Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NCSearch for more papers by this authorGrace M. Davainis, Grace M. Davainis Department of Veterinary Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NCSearch for more papers by this authorDavid M. Ruslander, David M. Ruslander Department of Veterinary Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NCSearch for more papers by this authorCarol B. Grindem, Carol B. Grindem Department of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, NCSearch for more papers by this author Eleanor C. Hawkins DVM, DACVIM (SAIM), Eleanor C. Hawkins DVM, DACVIM (SAIM) Department of Veterinary Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, 27606; e-mail: eleanor_hawkins@ncsu.edu.Search for more papers by this authorAmy M. Grooters, Amy M. Grooters Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA.Search for more papers by this authorElizabeth S. Cowgill, Elizabeth S. Cowgill Department of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, NCSearch for more papers by this authorDavid R. Proulx, David R. Proulx Department of Veterinary Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NCSearch for more papers by this authorGrace M. Davainis, Grace M. Davainis Department of Veterinary Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NCSearch for more papers by this authorDavid M. Ruslander, David M. Ruslander Department of Veterinary Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NCSearch for more papers by this authorCarol B. Grindem, Carol B. Grindem Department of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, NCSearch for more papers by this author First published: 05 February 2008 https://doi.org/10.1111/j.1939-1676.2006.tb00769.xCitations: 11 AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References 1 Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13: 236– 301. 2 Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: A review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004; 10: 31– 47. 3 Grooters AM. Pythiosis, lagenidiosis, and zygomycosis in small animals. Vet Clin North Am Small Anim Pract 2003; 33: 695– 720. 4 Humber RA, Brown CC, Kornegay RW. Equine zygomycosis caused by Conidiobolus lamprauges. J Clin Microbiol 1989; 27: 573– 576. 5 Temple ME, Brady MT, Koranyi KI, et al. Periorbital cellulitis secondary to Conidiobolus incongruus. Pharmacotherapy 2001; 21: 351– 354. 6 Sharma NL, Mahajan VK, Singh P. Orofacial conidiobolo-mycosis due to Conidiobolus incongruus. Mycoses 2003; 46: 137– 140. 7 Khan ZU, Khoursheed M., Makar R., et al. Basidiobolus ranarum as an etiologic agent of gastrointestinal zygomycosis. J Clin Microbiol 2001; 39: 2360– 2363. 8 Zamos DT, Schumacher J., Loy JK. Nasopharyngeal conidiobolomycosis in a horse. J Am Vet Med Assoc 1996; 208: 100– 101. 9 Ketterer PJ, Kelly MA, Connole MD, et al. Rhinocerebral and nasal zygomycosis in sheep caused by Conidiobolus incongruus. Aust Vet J 1992; 69: 85– 87. 10 Morris M., Ngeleka M., Adogwa AO, et al. Rhinocerebral zygomycosis in a sheep. Can Vet J 2001; 42: 227– 228. 11 Carrigan MJ, Small AC, Perry GH. Ovine nasal zygomycosis caused by Conidiobolus incongruus. Aust Vet J 1992; 69: 23– 240. 12 Bauer RW, LeMarie SL, Roy AF. Oral conidiobolomycosis in a dog. Vet Dermatol 1997; 8: 115– 120. 13 Hillier A., Kunkle GA, Ginn PE, et al. Canine subcutaneous zygomycosis caused by Conidiobolus sp: A case report and review of Conidiobolus infections in other species. Vet Dermatol 1994; 5: 205– 213. 14 French RA, Ashworth CD. Zygomycosis caused by Conidiobolus coronatus in a llama (Lama glama). Vet Pathol 1994; 31: 120– 122. 15 Moll HD, Schumacher J., Hoover TR. Entomophthoramycosis conidiobolae in a llama. J Am Vet Med Assoc 1992; 200: 969– 970. 16 Stephens CP, Gibson JA. Disseminated zygomycosis caused by Conidiobolus incongruus in a deer. Aust Vet J 1997; 75: 358– 359. 17 Steiger RR, Williams MA. Granulomatous tracheitis caused by Conidiobolus coronatus in a horse. J Vet Intern Med 2000; 14: 311– 314. 18 King JC, Dunphy D. Fatal phycomycosis without underlying disease. J Iowa Med Soc 1972; 62: 485– 488. 19 King DS, Jong SC. Identity of the etiological agent of the first deep entomophthoraceous infection of man in the United States. Mycologia 1976; 68: 181– 183. 20 Eckert HL, Khoury GH, Pore RS, et al. Entomophthora phycomycotic infection reported for the first time in the United States. Chest 1972; 61: 392– 394. 21 Busapakum R., Youngchaiyud U., Sriumpai S., et al. Disseminated infection with Conidiobolus incongruus. Sabouraudia 1983; 21: 323– 330. 22 Jaffey PB, Haque AK, El-Zaatari M., et al. Disseminated Conidiobolus infection with endocarditis in a cocaine abuser. Arch Pathol Lab Med 1990; 114: 1276– 1278. 23 Walker SD, Clark RV, King CT, et al. Fatal disseminated Conidiobolus coronatus infection in a renal transplant patient. Am J Clin Pathol 1992; 98: 559– 564. 24 Affolter VK, Moore PF. Canine cutaneous and systemic histiocytosis: Reactive histiocytosis of dermal dendritic cells. Am J Dermatopathol 2000; 21: 40– 48. 25 Espinel-Ingroff A. Utility of mould susceptibility testing. Curr Opin Infect Dis 2003; 16: 527– 532. Citing Literature Volume20, Issue6November 2006Pages 1479-1482 ReferencesRelatedInformation}, number={6}, journal={Journal of Veterinary Internal Medicine}, author={Hawkins, Eleanor and Grooters, A. M. and Cowgill, E. S. and Proulx, D. R. and Davainis, G. M. and Ruslander, D. M. and Grindem, C. B.}, year={2006}, pages={1479–1482} } @article{scarantino_ruslander_rini_mann_nagle_black_2004, title={An implantable radiation dosimeter for use in external beam radiation therapy}, volume={31}, ISSN={["2473-4209"]}, DOI={10.1118/1.1778809}, abstractNote={An implantable radiation dosimeter for use with external beam therapy has been developed and tested both in vitro and in canines. The device uses a MOSFET dosimeter and is polled telemetrically every day during the course of therapy. The device is designed for permanent implantation and also acts as a radiographic fiducial marker. Ten dogs (companion animals) that presented with spontaneous, malignant tumors were enrolled in the study and received an implant in the tumor CTV. Three dogs received an additional implant in collateral normal tissue. Radiation therapy plans were created for the animals and they were treated with roughly 300 cGy daily fractions until completion of the prescribed cumulative dose. The primary endpoints of the study were to record any adverse events due to sensor placement and to monitor any movement away from the point of placement. No adverse events were recorded. Unacceptable device migration was experienced in two subjects and a retention mechanism was developed to prevent movement in the future. Daily dose readings were successfully acquired in all subjects. A rigorous in vitro calibration methodology has been developed to ensure that the implanted devices maintain an accuracy of ±3.5% relative to an ionization chamber standard. The authors believe that an implantable radiation dosimeter is a practical and powerful tool that fosters individualized patient QA on a daily basis.}, number={9}, journal={MEDICAL PHYSICS}, author={Scarantino, CW and Ruslander, DM and Rini, CJ and Mann, GG and Nagle, HT and Black, RD}, year={2004}, month={Sep}, pages={2658–2671} } @article{williams_johnson_hauck_ruslander_price_thrall_2004, title={Chemotherapy followed by half-body radiation therapy for canine lymphoma}, volume={18}, ISSN={["1939-1676"]}, DOI={10.1892/0891-6640(2004)18<703:CFBHRT>2.0.CO;2}, abstractNote={A protocol of induction chemotherapy followed by half-body radiation therapy for treatment of lymphoma was used in 94 dogs. Seventy-three (78%) dogs achieved complete remission. Substage (P = .011) and phenotype (P = .015) were identified as predictors of complete remission rate. Of these, 52 dogs received half-body irradiation. Cranial and caudal halves received a total dose of 8.0 Gy, given in 2 fractions of 4.0 Gy on consecutive days with cobalt-60 photons and a 3-week interval between halves. Median 1st remission for these dogs was 311 days. Anemia was identified as the only predictor for length of 1st remission (P = .024). Toxicoses after half-body irradiation generally were mild and infrequent and included myelosuppression and gastrointestinal signs. Thirty-one dogs relapsed and 20 resumed treatment with induction followed by maintenance chemotherapy. Seventeen (85%) dogs achieved a 2nd complete remission. Median overall remission for all 52 dogs was 486 days. Results of this study suggest that half-body radiation therapy after induction chemotherapy is well tolerated and might increase remission duration compared with conventional protocols that use chemotherapy alone, but this increase might not be long enough to be clinically relevant or to justify application of the method described herein.}, number={5}, journal={JOURNAL OF VETERINARY INTERNAL MEDICINE}, author={Williams, LE and Johnson, JL and Hauck, ML and Ruslander, DM and Price, GS and Thrall, DE}, year={2004}, pages={703–709} } @article{birkenheuer_neel_ruslander_levy_breitschwerdt_2004, title={Detection and molecular characterization of a novel large Babesia species in a dog}, volume={124}, ISSN={0304-4017}, url={http://dx.doi.org/10.1016/j.vetpar.2004.07.008}, DOI={10.1016/j.vetpar.2004.07.008}, abstractNote={Babesia canis has generally been considered the only large Babesia to infect dogs. Here we describe the molecular characterization of a large Babesia species that was detected in the blood and bone marrow of a dog with clinical and hematological abnormalities consistent with babesiosis. Analysis of the 18S rRNA genes revealed a unique sequence that shared 93.9% sequence identity with B. bigemina and 93.5% sequence identity with B. caballi, compared to 91.2-91.6% identity with B. canis canis, B. c. vogeli, and B. c. rossi. Cross-reactive antibodies against B. canis, B. gibsoni (Asian genotype), or B. gibsoni (California genotype) antigens were not detected in acute or convalescent serum samples. The dog was treated with imidocarb diproprionate, which resulted in the resolution of clinical signs, and subsequently Babesia DNA was not detectable by PCR in post-treatment samples. The organism described in this report represents a genetically unique large Babesia sp. and is the eighth genetically distinct piroplasm capable of infecting the domestic dog.}, number={3-4}, journal={Veterinary Parasitology}, publisher={Elsevier BV}, author={Birkenheuer, A.J. and Neel, J. and Ruslander, D. and Levy, M.G. and Breitschwerdt, E.B.}, year={2004}, month={Oct}, pages={151–160} } @article{cowgill_neel_ruslander_2004, title={Light-chain myeloma in a dog}, volume={18}, ISSN={["1939-1676"]}, url={http://www.scopus.com/inward/record.url?eid=2-s2.0-0842265687&partnerID=MN8TOARS}, DOI={10.1892/0891-6640(2004)18<119:LMIAD>2.0.CO;2}, number={1}, journal={JOURNAL OF VETERINARY INTERNAL MEDICINE}, author={Cowgill, ES and Neel, JA and Ruslander, D}, year={2004}, pages={119–121} } @article{ruslander_2002, title={Why all 57Gy protocols are not created equal! Understanding treatment volumes and dose prescription}, volume={26}, number={2}, journal={Veterinary Cancer Society Newsletter}, author={Ruslander, D.}, year={2002}, pages={7} } @article{ruslander_page_1995, title={PERIOPERATIVE MANAGEMENT OF PARANEOPLASTIC SYNDROMES}, volume={25}, ISSN={["0195-5616"]}, DOI={10.1016/S0195-5616(95)50004-X}, abstractNote={This discussion of paraneoplasia is by no means exhaustive, but it does represent the more common conditions seen in the surgical oncology patient. A thorough understanding of biologic behavior of different tumor types allows the surgeon to recognize cases in which special attention is needed for the management of paraneoplastic syndromes. In this way, problems are averted, minimizing risk to the patient and increasing the likelihood of a successful surgical outcome.}, number={1}, journal={VETERINARY CLINICS OF NORTH AMERICA-SMALL ANIMAL PRACTICE}, author={RUSLANDER, D and PAGE, R}, year={1995}, month={Jan}, pages={47–62} }